Miglustat

FDA Approved: * April 17, 2018
Category: Enzymes

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Miglustat Overview

Miglustat (OGT 918, N-butyl-deoxynojirimycin) is a drug developed by Oxford GlycoSciences and marketed by Actelion and is used primarily to treat type I Gaucher disease (GD1). It is marketed under the trade name Zavesca. Contents 1 Medical uses 2 Contraindications 3 Adverse effects 4 Mechanism of action 5 Chemistry 6 Research 7 See also 8 References Medical uses Miglustat is used to treat adults with mild-to-moderate type I Gaucher disease for whom enzyme replacement therapy is unsui...

Read more Miglustat Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Miglustat

Recent Miglustat Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Miglustat: (2 results)

Sorted by National Drug Code

• 10148-201 Miglustat 100 mg Oral Capsule by Cotherix, Inc.
• 43975-310 Miglustat 100 mg Oral Capsule by Amerigen Pharmaceuticals Inc.

Other drugs which contain Miglustat or a similar ingredient: (1 result)

• ZAVESCA Miglustat